ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rare Disease

Sarepta and Codiak to develop exosome-based therapies

by Ryan Cross
June 26, 2020 | APPEARED IN VOLUME 98, ISSUE 25

 

Sarepta Therapeutics, a rare-disease company known for its Duchenne muscular dystrophy therapies, has formed a research pact with Codiak BioSciences, a start-up that is engineering lipid vesicles called exosomes as delivery vessels for genetic therapies. The pair will use Codiak’s exosomes in gene replacement, gene editing, and RNA therapies for up to five neuromuscular disease targets. Codiak could receive as much as $72.5 million in up-front and near-term payments in the 2-year pact.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment